Bayer’s Eylea Shot Down By IQWiG On A Technicality
This article was originally published in The Pink Sheet Daily
Germany’s IQWiG has tightened the screw on reimbursement submissions, rejecting Bayer’s Eylea for AMD on technical grounds concerning its comparator.
You may also be interested in...
Changes to Germany’s drug reimbursement law have permitted Boehringer Ingelheim and Eli Lilly to submit an updated dossier for their oral therapy Trajenta, giving medicine makers who operate there hope that further positive amendments will occur.
Eylea manufacturer Regeneron says the new treatment for wet AMD is being reimbursed by all regional Medicare claims contractors.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.